Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad's MyChoice Tests) is now available in Argentina, Braz ...